Factors associated with high 24-month persistence with denosumab: results of a real-world non-interventional study of women with postmenopausal osteoporosis in Germany Austria Greece and Belgium

摘要

SummaryPersistence with osteoporosis therapy is vital for fracture prevention. This non-interventional study of postmenopausal women receiving denosumab in Germany, Austria, Greece, and Belgium found that persistence with denosumab remains consistently high after 24 months in patients at high risk of fracture.